164 related articles for article (PubMed ID: 37865999)
1. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
[TBL] [Abstract][Full Text] [Related]
2. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
3. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
4. An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.
Wang Y; Jiang H; Luo H; Sun Y; Shi B; Sun R; Li Z
Front Immunol; 2019; 10():1691. PubMed ID: 31379876
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract][Full Text] [Related]
6. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
7. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
8. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
9. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
10. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
11. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
[TBL] [Abstract][Full Text] [Related]
12. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.
Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T
Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304
[TBL] [Abstract][Full Text] [Related]
14. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
15. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract][Full Text] [Related]
16. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
18. A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells.
Guo C; Dong M; Wang X; Yu J; Jin X; Cheng S; Cui F; Qian Y; Bao Q; Zhi L; Niu Z; Li M; Zhu W
Biochem Biophys Res Commun; 2024 May; 710():149918. PubMed ID: 38598902
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.
Zhang Y; Zhang C; He M; Xing W; Hou R; Zhang H
BMC Cancer; 2024 Jan; 24(1):119. PubMed ID: 38263004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]